european medicines agency glp-1 vision loss recommendation november 2025 Exploring the Side Effects of Receptor Agonist: To Ensure Its Optimal Positioning Eye disorder is a 'very

Even if you meet the diagnostic criteria weve discussed, you would not be indicated for a weight loss peptide if you are: Pregnant Animal studies show that the offspring of pregnant subjects exposed to GLP-1 RAs may develop skeletal abnormalities, have a low birth weight, and exhibit substandard growth.23 Although no congenital malformations have been widely identified in humans, people who are pregnant or planning to become pregnant are advised to forgo or end their GLP-1 RA treatment

[13] In combination with a reduced-calorie diet and increased physical activity, semaglutide (as Wegovy) is indicated to reduce the risk of major adverse cardiovascular events (cardiovascular death, non-fatal myocardial infarction, or non-fatal stroke) in adults with established cardiovascular disease and who are either obese or overweight

doi: 10.1016/j.bbrc.2005.09.121

Who lose weight at comparable rates to high-dose tirzepatide users